Proactive Investors
21 May 2026, 15:47 UTC · 3h ago
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Source · https://www.proactiveinvestors.com/companies/news/1092705
Read source
Search tags
Proactive Investors
21 May 2026, 15:47 UTC · 3h ago
Source · https://www.proactiveinvestors.com/companies/news/1092705
Read sourceSearch tags
Story key points
2 claims · impact-rated
Tiziana Life Sciences has completed patient enrollment for its Phase 2a clinical trial (INFORM-MS) of intranasal foralumab for non-active secondary progressive multiple sclerosis. — Completing enrollment is a critical operational milestone that removes a primary execution risk and moves the company closer to data readout.
+0.40Topline results from the Phase 2a trial are expected in the late third quarter of 2026, with further data presentation in October 2026. — This establishes a concrete catalyst date for the stock, creating a timeline for potential volatility based on efficacy and safety results.
+0.30Impact vectors
2 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company completed patient enrollment in a Phase 2a clinical trial for its lead drug candidate, marking a key milestone.
No ticker relationship head found.